Fourth-Quarter and Full-Year 2019 Orphan and Rheumatology Segment Results

Fourth-Quarter and Full-Year 2019 Inflammation Segment Results ($M) PENNSAIDⓇ 2% DUEXISⓇ VIMOVO® MIGERGOTⓇ(1) Inflammation segment net sales Q4 2019 Q4 2018 % Change FY 2019 FY 2018 % Change $57.0 $64.3 (11) $200.8 $190.2 6 26.3 34.0 (23) 115.7 114.7 1 10.4 18.8 (45) 52.1 67.6 (23) 0.8 NM 1.8 3.6 (49) $93.7 $117.9 (21) $370.4 $376.1 (2) Inflammation segment operating income $44.0 $66.2 (33) $174.9 $160.4 9 (1) In June 2019, the Company divested the rights to MIGERGOT. HORIZON 42

View entire presentation